The Proportion of Non-retention and Its Associated Factors Among Clients Receiving Methadone Maintenance Therapy in Kelantan, Malaysia

Article Sidebar

PDF
Published: Apr 30, 2021
Keywords:
Methadone maintenance therapy, Non-retention, Opioid, Malaysia

Main Article Content

Mohd Hazwan Baharuddin
Department of Community Medicine, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
Mohd Azhar Mohd Yasin
Department of Psychiatry, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
Mohd Nazri Shafei
Department of Community Medicine, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

Abstract

Introduction: Methadone maintenance therapy (MMT) requires a client to take a daily dose of methadone to reduce cravings for opioid and suppress withdrawal syndrome. Non-retention in the MMT will seriously expose more risk rather than the benefits of the program. Hence, determining the factors associated with non-retention to the MMT is essential. Thus, the present study was conducted to determine the proportion of non-retention and its associated factors among clients receiving MMT in Kelantan, Malaysia. Methods: By using a retrospective record review anal- ysis, the required information of the clients was obtained from fourteen MMT clinics in Kelantan, Malaysia. A total of 155 clients were selected in this study using systematic random sampling. Multiple logistic regression analysis was performed to determine the factors associated with non-retention among clients receiving MMT. Results: It was found that the proportion of non-retention to the MMT in Kelantan, Malaysia was 21.9%. Clients with advanced age, taking daily direct observed therapy, and no underlying HIV were the predictors of non-retention among clients re- ceiving MMT in Kelantan, Malaysia. Conclusion: The findings highlight a relatively high proportion of non-retention among the MMT clients. There is a need for an integrated, culturally relevant approach towards tackling the factors associated with non-retention in the future to keep this program sustainable and effective.

Downloads

Download data is not yet available.

Article Details

How to Cite
Baharuddin, M. H., Mohd Yasin, M. A., & Shafei, M. N. (2021). The Proportion of Non-retention and Its Associated Factors Among Clients Receiving Methadone Maintenance Therapy in Kelantan, Malaysia. Malaysian Journal of Medicine and Health Sciences, 17(2), 11–17. Retrieved from http://mjmhsojs.upm.edu.my/index.php/mjmhs/article/view/259
Issue
Vol. 17 No. 2 (2021)
Section
Original Articles

References

Oprea C, Ianache I, Calistru PI, et al. Increasing incidence of HIV- associated tuberculosis in Romanian injecting drug users. HIV Med. 2018;19(5):316-23.

Joseph H, Stancliff S, Langrod J. Methadone Maintenance Treatment (MMT): a review of historical and clinical issue. Mt Sinai J Med. 2000;67.

Shen J, Wang M, Wang X, et al. Predictors of Poor Adherence to Methadone Maintenance Treatment in Yunnan Province, China. J Addict Med. 2016;10(1):40-5.

O’Keefe D, Stoové M, Doyle J, Dietze P, Hellard M. Injecting drug use in low and middle- income countries: Opportunities to improve care and prevent harm. Journal of Viral Hepatitis. 2017;24(9):714-24.

Ali N, Aziz SA, Nordin S, et al. Evaluation of Methadone Treatment in Malaysia: Findings from the Malaysian Methadone Treatment Outcome Study (MyTOS). Subst Use Misuse. 2018;53(2):239- 48.

Kelly SM, Schwartz RP, O’Grady K E, Gandhi D, Jaffe JH. Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial. J Addict Med. 2012;6(2):145-52.

Walley AY, Cheng DM, Pierce CE, et al. Methadone dose, take home status, and hospital admission among methadone maintenance patients. J Addict Med. 2012;6(3):186-90.

Lin C, Wu Z, Detels R. Opiate users’ perceived barriers against attending methadone maintenance therapy: a qualitative study in China. Subst Use Misuse. 2011;46.

Moreira Tde C, Figueiro LR, Fernandes S, et al. Quality of life of users of psychoactive substances, relatives, and non-users assessed using the WHOQOL-BREF. Cien Saude Colet. 2013;18(7):1953-62.

Kamarulzaman A, Altice FL. Challenges in managing HIV in people who use drugs. Current Opinion in Infectious Diseases. 2015;28(1):10-6.

de Bresser I, Remers TEP, Wieland MWM, Prawiranegara R, Siregar AYM, Baltussen R. Prioritizing HIV/AIDS prevention strategies in Bandung, Indonesia: A cost analysis of three different HIV/AIDS interventions. PLoS One. 2019;14(8):e0221078.

Ramli M, Zafri AB, Junid MR, Hatta S. Associated risk factors to Non-compliance to Methadone Maintenance Therapy. The Medical journal of Malaysia. 2012;67(6):560-4.

Sharifa Ezat WP, Noor Azimah H, Rushidi R, Raminder K, Ruhani I. Compliance towards methadone maintenance therapy and its associated factors in Selangor primary care centers and Kuala Lumpur hospital. The Medical journal of Malaysia. 2009;64(1):65-70.

Smyth BP, Elmusharaf K, Cullen W. Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months. BMC Pediatr. 2018;18(1):151.

Sarasvita R, Tonkin A, Utomo B, Ali R. Predictive factors for treatment retention in methadone programs in Indonesia. Journal of substance abuse treatment. 2012;42(3):239-46.

Yang F, Lin P, Li Y, et al. Predictors of retention in community-based methadone maintenance treatment program in Pearl River Delta, China. Harm reduction journal. 2013;10:3.

Zhou K, Zhuang G. Retention in methadone maintenance treatment in mainland China, 2004- 2012: a literature review. Addictive behaviors. 2014;39(1):22-9.

Eibl JK, Gomes T, Martins D, et al. Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada. J Addict Med. 2015;9(6):440-6.

Gao L, Dimitropoulou P, Robertson JR, McTaggart S, Bennie M, Bird SM. Risk-factors for methadone- specific deaths in Scotland’s methadone- prescription clients between 2009 and 2013. Drug Alcohol Depend. 2016;167:214-23.

Pierce M, Millar T, Robertson JR, Bird SM. Ageing opioid users’ increased risk of methadone-specific death in the UK. Int J Drug Policy. 2018;55:121-7.

Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. Circulation. 2016;133(2):187-225.

Vallecillo G, Robles MJ, Torrens M, et al. Metabolic syndrome among individuals with heroin use disorders on methadone therapy: Prevalence, characteristics, and related factors. Subst Abus. 2018;39(1):46-51.

Howard AA, Floris-Moore M, Lo Y, Arnsten JH, Fleischer N, Klein RS. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med. 2006;7(6):389-96.

Toce MS, Chai PR, Burns MM, Boyer EW. Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity. J Med Toxicol. 2018;14(4):306-22.

Hejazi N, Huang MS, Lin KG, Choong LC. Hypertension among HIV-infected adults receiving highly active antiretroviral therapy (HAART) in Malaysia. Glob J Health Sci. 2013;6(2):58-71.

Brust JC, Litwin AH, Berg KM, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance. AIDS Res Hum Retroviruses. 2011;27(5):535-41.

Zhao Y, Shi CX, McGoogan JM, Rou K, Zhang F, Wu Z. Predictors of accessing antiretroviral therapy among HIV-positive drug users in China’s National Methadone Maintenance Treatment Programme. Addiction. 2015;110 Suppl 1:40-50.

Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. International Journal of Drug Policy. 2010;21(2):122-4.

Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV- infected patients in a methadone program. Clin Infect Dis. 2004;38 Suppl 5:S402-8.

Lappalainen L, Nolan S, Dobrer S, et al. Dose- response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction. 2015;110(8):1330-9.

Cousins G, Boland F, Barry J, et al. J-shaped relationship between supervised methadone consumption and retention in methadone maintenance treatment (MMT) in primary care: National cohort study. Drug Alcohol Depend. 2017;173:126-31.

Saulle R, Vecchi S, Gowing L. Supervised dosing with a long-acting opioid medication in the management of opioid dependence. Cochrane Database Syst Rev. 2017;4:Cd011983.

Gerra G, Saenz E, Busse A, et al. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):483-9.

Notley C, Holland R, Maskrey V, Nagar J, Kouimtsidis C. Regaining control: the patient experience of supervised compared with unsupervised consumption in opiate substitution treatment. Drug Alcohol Rev. 2014;33(1):64-70.

Adelson M, Wilson HW, Celeste VY, Linzy S, Kreek MJ, Peles E. Methadone maintenance treatment experience in Macao--prospective follow-up for initial 4.5 years. J Psychoactive Drugs. 2013;45(4):313-21.

Peles E, Schreiber S, Domany Y, Sason A, Tene O, Adelson M. Achievement of take-home dose privileges is associated with better-perceived sleep and with cognitive status among methadone maintenance treatment patients. World J Biol Psychiatry. 2014;15(8):620-8.

Peles E, Schreiber S, Sason A, Adelson M. Earning “take-home” privileges and long-term outcome in a methadone maintenance treatment program. J Addict Med. 2011;5(2):92-8.

Varenbut M, Teplin D, Daiter J, et al. Tampering by office-based methadone maintenance patients with methadone take home privileges: a pilot study. Harm reduction journal. 2007;4:15.

Chawarski MC, Vicknasingam B, Mazlan M, Schottenfeld RS. Lifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia. Drug Alcohol Depend. 2012;124(1- 2):177-80.

Lua PL, Talib NS. A 12-month evaluation of health- related quality of life outcomes of methadone maintenance program in a rural Malaysian sample. Substance use & misuse. 2012;47(10):1100-5.

Musa R, Abu Bakar AZ, Ali Khan U. Two-year outcomes of methadone maintenance therapy at a clinic in Malaysia. Asia Pacific Journal of Public Health. 2012;24(5):826-32.

Vijay A, Bazazi AR, Yee I, Kamarulzaman A, Altice FL. Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia. Journal of substance abuse treatment. 2015;54:29-36.